
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
AIXIAL has announced the acquisition of UK headquartered CMED Group by ALTEN EUROPE. CMED is a technology led CRO that specializes in full-service oncology, immuno-oncology, cell therapy and rare diseases, and provision of data and analytic services. CMED also has a technology division that is the developer of encapsia, a clinical data suite purpose designed to support traditional, decentral, virtual and hybrid clinical trials.
AIXIAL Group continues to build a global presence in size and scale with over 1,000 employees across the United States and Europe.
For more information, click






